Get in Touch

We developed a GT monthly tracker for large pharma with multiple GT assets in pipeline ​

  • Value Communication, Digital Solutions
P4A have provided very valuable competitive intelligence insights and translated this into strategic, tailored recommendations​
Global Market Access ​ Director​

Client Challenge

Needed a competitive intelligence partner to support decision making for GTs​

A large Pharma company, with multiple gene therapies in their pipeline, was trying to enter several competitively intense disease areas ​

There were seeking a partner to provide competitive intelligence and recommendations across different disease areas, to help make them informed decisions about their late stage GT assets ​

P4A Solution

P4A developed a competitive intelligence tracker to capture relevant insights on launched GTs and appropriate disease specific competitors

P4A addressed this using a three step approach:​
  1. Conduct in-depth review with asset teams, aligning on key areas of focus to ensure tailored insights and recommendations for their GT assets ​
  2. Develop a monthly report addressing the areas of focus for the asset teams ​
  3. Align regularly to ensure reports consistently meet the evolving needs of each asset team ​

The Successful Outcome​

  • Developed a monthly report including insights from a regulatory, early access, HTA, pricing & contracting, and strategy perspective across multiple launched GTs and relevant non-GT competitors. This included: ​
    • Insights and key learnings from select CGT conferences​
    • Recommendations and key considerations for the GT strategy based on the insights gathered ​
  • Provided ad-hoc updates and key considerations, in the form of email blasts, when relevant breaking news occurred that could affect the company’s asset and strategy ​

Need more details?

Do you want to learn more about the successful outcome for this case study? Are you interested in P4A Services or just want to say Hi?

get in touch

Explore other case studies

Understand evidence requirements beyond clinical trial data for launching an orphan drug in Türkiye & the GCC

  • Access Strategy

Optimising the PRMA potential of an orphan oncology asset in EU4 + UK and Japan

  • Access Strategy, Price Optimisation
p4a-logo-small-retina-white

We are award winning global experts in access for orphan drugs and Cell and Gene Therapies.

Twitter Instagram Youtube Linkedin

About

Services

Insights

Case Studies

Contact

  • Aramislaan 88,
  • 6213BV Maastricht, Netherlands
  • +31 6 55 88 71 96
  • contact@partners4access.com

P4A Services

For all access and Rare Disease related overview enquiries